Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives Average Recommendation of “Moderate Buy” from Analysts

Lantheus Holdings, Inc. (NASDAQ:LNTH) has been given an average recommendation of “Moderate Buy” by the eleven analysts that are covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $101.8571.

LNTH has been the subject of several analyst reports. Truist Financial restated a “buy” rating and set a $115.00 target price (up from $98.00) on shares of Lantheus in a research report on Monday, May 11th. Weiss Ratings restated a “hold (c)” rating on shares of Lantheus in a research report on Tuesday. JonesTrading downgraded Lantheus from a “buy” rating to a “hold” rating in a research report on Friday, February 27th. William Blair restated an “outperform” rating on shares of Lantheus in a research report on Tuesday, March 17th. Finally, Citizens Jmp upped their price objective on shares of Lantheus from $85.00 to $115.00 and gave the stock a “market outperform” rating in a research note on Friday, May 8th.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of LNTH. M&T Bank Corp acquired a new stake in Lantheus during the 4th quarter valued at $370,950,000. Farallon Capital Management LLC increased its holdings in Lantheus by 56.1% during the 4th quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock valued at $361,199,000 after purchasing an additional 1,950,252 shares in the last quarter. Norges Bank acquired a new stake in Lantheus during the 4th quarter valued at $76,197,000. Freestone Grove Partners LP raised its holdings in shares of Lantheus by 4,114.8% in the fourth quarter. Freestone Grove Partners LP now owns 608,526 shares of the medical equipment provider’s stock valued at $40,497,000 after buying an additional 594,088 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund raised its holdings in shares of Lantheus by 686.1% in the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 598,857 shares of the medical equipment provider’s stock valued at $45,423,000 after buying an additional 522,678 shares during the last quarter. Institutional investors own 99.06% of the company’s stock.

Lantheus Stock Up 0.5%

Shares of LNTH opened at $99.62 on Friday. The stock has a market cap of $6.49 billion, a price-to-earnings ratio of 24.00 and a beta of -0.08. The company has a quick ratio of 2.64, a current ratio of 2.83 and a debt-to-equity ratio of 0.47. Lantheus has a 12 month low of $47.25 and a 12 month high of $103.89. The company has a 50-day moving average price of $85.28 and a two-hundred day moving average price of $73.15.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 EPS for the quarter, topping analysts’ consensus estimates of $1.25 by $0.21. The firm had revenue of $377.33 million during the quarter, compared to analysts’ expectations of $354.48 million. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The company’s revenue for the quarter was up 1.2% compared to the same quarter last year. During the same quarter last year, the company earned $1.53 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Equities analysts predict that Lantheus will post 4.41 EPS for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.